BOSTON — The drug industry has spent the past year speaking against new mechanisms that could limit how much governments or insurers pay for certain new medicines. Robert Califf, the Food and Drug Administration chief, walked on stage Wednesday and told a crowd of biotech leaders that drug costs needed fixing.
“We don’t agree,” said Califf, referring to a conversation he had backstage with Ted Love, the new chair of the Biotechnology Innovation Organization. “I think the prices of drugs are too high in the U.S.”
Califf has an apparent habit of walking into industry meetings and saying precisely what that industry doesn’t want to hear. He also spent much of his career working on new ways of generating decisive evidence for therapies and other medical interventions.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect